Rocket Pharmaceuticals (RCKT)

• Market cap: $429M
• 1 day: -4.52%
• 5 days: -10.59%
• 1 month: 19.5%
• 3 months: 12.76%
• 6 months: -45.48%
• Year to date: -70.13%
• 1 year: -78.53%
• 5 years: -86.81%
• 10 years: -90.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 299